Should I buy or sell AstraZeneca stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AZN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AZN, but not buy additional shares or sell existing shares. View AZN analyst ratings or view top-rated stocks .

What is AstraZeneca's stock price target for 2024?

9 brokers have issued twelve-month target prices for AstraZeneca's stock. Their AZN share price targets range from GBX 9,500 to £129. On average, they expect the company's stock price to reach £115.43 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View analysts price targets for AZN or view top-rated stocks among Wall Street analysts .

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at £106 on January 1st, 2024. Since then, AZN shares have increased by 4.0% and is now trading at £110.24. View the best growth stocks for 2024 here .

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, February 8th. Shareholders of record on Thursday, February 22nd will be given a dividend of GBX 156 per share on Monday, March 25th. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is a boost from the stock's previous dividend of GBX 71.80. The official announcement can be viewed at this link . Read our dividend analysis for AZN .

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 228 per share and currently has a dividend yield of 2.06%. The dividend payout ratio is 7,524.75%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for AZN .

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Intel (INTC) , Vodafone Group Public (VOD) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , Pfizer (PFE) , QUALCOMM (QCOM) and The Hain Celestial Group (HAIN) .

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:AZN

AstraZeneca (AZN) Share Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free AZN Stock Alerts

£109.48

-76.00 (-0.69%)

(As of 04:27 AM ET)

Compare

Today's Range: £108.22
▼
£109.66
50-Day Range: 9,501
▼
£110.64
52-Week Range: 9,461
▼
£123.92

Volume: 175,514 shs
Average Volume: 2.18 million shs
Market Capitalization: £169.69 billion

P/E Ratio: 3,613.20
Dividend Yield: 2.08%
Price Target: £115.43

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

Get AstraZeneca alerts:

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating: Hold
2.44 Rating Score
Upside/Downside: 4.7% Upside
£115.43 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.05
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

2.2

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 6 buy ratings, 1 hold rating, and 2 sell ratings.
Amount of Analyst Coverage
AstraZeneca has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for AZN.

0.8

Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 2.06%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 7,524.75%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AstraZeneca has received a 55.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Osimertinib", "Olaparib", "SGLT2 inhibitors", "Durvalumab", "Asthma inhalers", and "Antiplatelet medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AstraZeneca is -2.35.

1.7

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for AstraZeneca this week, compared to 2 articles on an average week.
Search Interest
Only 22 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.23% of the stock of AstraZeneca is held by insiders.
Percentage Held by Institutions
50.78% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 3,638.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 142.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 3,638.28, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 249.28.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About AstraZeneca Stock (LON:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AZN Stock News Headlines

April 16, 2024 | americanbankingnews.com

AstraZeneca (LON:AZN) Receives "Buy" Rating from Shore Capital

April 11, 2024 | msn.com

UK Stocks: AstraZeneca (AZN) Assures Dividend Growth Before CEO Pay Vote

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 11, 2024 | uk.investing.com

Lok’nStore, AstraZeneca, Darktrace, Distil, European Metals, XPS Pensions, Mast Energy – Stocks on the move

April 11, 2024 | finance.yahoo.com

April 11, 2024 | americanbankingnews.com

AstraZeneca (LON:AZN) Sets New 1-Year Low at $105.92

April 11, 2024 | marketwatch.com

AstraZeneca: Board to Raise Annualised Div by $0.20 to $3.10 Per Shr

April 9, 2024 | americanbankingnews.com

Barclays Reiterates Overweight Rating for AstraZeneca (LON:AZN)

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 8, 2024 | msn.com

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

April 6, 2024 | americanbankingnews.com

AstraZeneca's (AZN) Buy Rating Reaffirmed at Shore Capital

April 5, 2024 | msn.com

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

April 3, 2024 | benzinga.com

A Closer Look at AstraZeneca's Options Market Dynamics

March 27, 2024 | msn.com

Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants

March 19, 2024 | msn.com

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

March 19, 2024 | nasdaq.com

AstraZeneca To Buy Fusion Pharma For Up To $2.4 Bln

March 16, 2024 | finance.yahoo.com

AZN Apr 2024 72.000 call

March 14, 2024 | finance.yahoo.com

AZN May 2024 67.500 call

March 5, 2024 | finance.yahoo.com

AZN Apr 2024 60.000 put

February 25, 2024 | finance.yahoo.com

AZN Apr 2024 67.000 call

February 23, 2024 | finance.yahoo.com

AZN Mar 2024 57.000 call

February 23, 2024 | finance.yahoo.com

AZN Mar 2024 68.000 put

February 22, 2024 | benzinga.com

AstraZeneca Stock (NASDAQ:AZN) Insider Trades

February 22, 2024 | markets.businessinsider.com

AstraZeneca Prices $5bln Four Tranche Notes Offering

February 20, 2024 | msn.com

Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca

February 19, 2024 | finance.yahoo.com

AZN Oct 2024 62.500 put

February 19, 2024 | markets.businessinsider.com

AstraZeneca's Tagrisso With Chemotherapy Approved In US To Treat Lung Cancer

See More Headlines

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/25 Dividend: 2/22/2024
Dividend Payable: 3/25/2024
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: LON:AZN
CUSIP: N/A
CIK: N/A
Web: www.astrazeneca.com
Phone: +44-20-73045000
Fax: N/A
Employees: 89,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: £115.43
High Stock Price Target: £129
Low Stock Price Target: GBX 9,500
Potential Upside/Downside: +4.7%
Consensus Rating: Hold
Rating Score (0-4): 2.44
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 3.03
Trailing P/E Ratio: 3,638.28
Forward P/E Ratio: 16.36
P/E Growth: 0.89
Net Income: £5.95 billion
Net Margins: 13.00%
Pretax Margin: N/A
Return on Equity: 15.64%
Return on Assets: 6.60%

Debt

Debt-to-Equity Ratio: 75.70
Current Ratio: 0.82
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: £45.81 billion
Price / Sales: 3.73
Cash Flow: GBX 283.46 per share
Price / Cash Flow: 38.89
Book Value: GBX 2,525 per share
Price / Book: 4.37

Miscellaneous

Outstanding Shares: 1,550,000,000
Free Float: N/A
Market Cap: £170.87 billion
Optionable: Not Optionable
Beta: 0.19

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Pascal Soriot D.V.M. (Age 65)
M.B.A., CEO & Executive Director
Comp: $4.57M
Dr. Aradhana Sarin M.D. (Age 50)
CFO & Executive Director
Comp: $2.52M
Ms. Pam P. Cheng (Age 54)
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett
Head of Investor Relations
Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina
Head of Global Media Relations
Dr. Menelas Nicolas Pangalos Ph.D. (Age 57)
Executive Vice-President
Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D. (Age 58)
Ph.D., Executive Vice President of Oncology Research & Development
Mr. Leon Wang
Executive VP of International & China President

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

AstraZeneca has a diverse portfolio of marketed products including Tagrisso, Imfinzi, and Lynparza, which are leading drugs in the oncology field.
The company has a strong presence in the cardiovascular and renal markets with products like Farxiga and Brilinta, providing a stable revenue stream.
AstraZeneca's collaboration agreements, such as the one with Neurimmune AG, demonstrate its commitment to innovation and expanding its product pipeline.
The company's focus on developing prescription medicines for various medical conditions positions it well in the healthcare industry, which is known for its stability.
Recent positive analyst recommendations and price targets for AstraZeneca's stock indicate potential growth and value for investors.

Cons

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

AstraZeneca faces competition from other pharmaceutical companies in the market, which could impact its market share and revenue growth.
The biopharmaceutical industry is subject to regulatory challenges and pricing pressures, affecting the profitability of companies like AstraZeneca.
Market volatility and economic uncertainties can influence the stock price of AstraZeneca, leading to potential investment risks.
Concerns about patent expirations for some of AstraZeneca's key products may impact future revenue streams and overall financial performance.
Investors need to consider the potential impact of geopolitical factors, global health crises, and regulatory changes on AstraZeneca's operations and market position.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AZN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AZN, but not buy additional shares or sell existing shares.
View AZN analyst ratings or view top-rated stocks.
What is AstraZeneca's stock price target for 2024?: 9 analysts have issued 1 year target prices for AstraZeneca's shares. Their AZN share price targets range from GBX 9,500 to £129. On average, they expect the company's stock price to reach £115.43 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.
How have AZN shares performed in 2024?: AstraZeneca's stock was trading at £106 at the beginning of the year. Since then, AZN shares have increased by 4.0% and is now trading at £110.24.
View the best growth stocks for 2024 here.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca declared a dividend on Thursday, February 8th. Shareholders of record on Thursday, February 22nd will be paid a dividend of GBX 156 per share on Monday, March 25th. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is a boost from the stock's previous dividend of GBX 71.80. The official announcement can be seen at this link.
Read our dividend analysis for AZN.

Is AstraZeneca a good dividend stock?: AstraZeneca (LON:AZN) pays an annual dividend of GBX 228 per share and currently has a dividend yield of 2.06%. The dividend payout ratio is 7,524.75%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.
What other stocks do shareholders of AstraZeneca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).
How do I buy shares of AstraZeneca?: Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AZN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AstraZeneca (AZN) Share Price, News & Analysis

AstraZeneca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AstraZeneca Stock (LON:AZN)

AZN Stock Price History

AZN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Cons

AZN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™